Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/1/1992


1.		Phase I/II Study of CTX/VCR/DOX/VP-16 with ddI, G-CSF, and CNS Prophylaxis/Therapy in Patients with AIDS-Associated non-Hodgkin's Lymphoma (Summary Last Modified 07/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NCI-92-C-0162 NCI-T92-0039N, T92-0039

Last Modified: 9/1/1993


2.		Phase I/II Study of ABV (DOX/BLEO/VCR) and ddI or ddC in Patients with Advanced AIDS-Related Kaposi's Sarcoma (Summary Last Modified 09/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				over 12				NIAID				NIAID-ACTG-163

Last Modified: 11/1/1994


3.		Phase II Pilot Study of CDE (CTX/DOX/VP-16) and G-CSF plus ddI for HIV-Related Intermediate- and High-Grade non-Hodgkin's Lymphoma (Summary Last Modified 11/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over								AECM-9312379 NCI-V94-0439

Last Modified: 11/12/2008


4.		Phase II Study of CDE (CTX/DOX/VP-16) plus ddI for HIV-Related Intermediate- and High-Grade non-Hodgkin's Lymphoma (Summary Last Modified 08/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				E-1494 E1494

Last Modified: 12/1/2000


5.		Phase II Study of Etoposide/Mitoxantrone/Prednimustine for Relapsed Disease and Cyclophosphamide/Doxorubicin/Etoposide for Refractory Disease in Patients with HIV-Associated non-Hodgkin's Lymphoma (Summary Last Modified 12/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								ITA-GICAT-C/941202-3 EU-96059, NCT00002905

Last Modified: 1/1/1998


6.		Phase II Pilot Study of Epirubicin/Bleomycin/Vinblastine/Prednisone with G-CSF and Either Zidovudine or Didanosine in HIV-Associated Hodgkin's Disease (Summary Last Modified 01/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 15								ITA-GICAT-C/890301 EU-96054

Last Modified: 2/1/1992


7.		Phase II Pilot Study of TRA and Antiretroviral Therapy in HIV-Related Kaposi's Sarcoma (Summary Last Modified 02/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				over 18 to less than 70				NCI				LAC-USC-17K911 NCI-T91-0126D, T91-0126

Last Modified: 3/1/2001


8.		Phase II Pilot Study of Chemotherapy in Children and Adolescents with non-Hodgkin's Lymphoma and Lymphoproliferative Disorders Associated with Congenital or Acquired Immunodeficiency Syndromes (Summary Last Modified 03/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				3 months to 18 years				NCI				NCI-93-C-0207B NCI-T93-0006N, T93-0006

Last Modified: 6/1/1995


9.		Phase I Study of Genetically Modified CD8+ HIV-Specific T Cells for HIV-Seropositive Patients Undergoing Allogeneic Bone Marrow or Syngeneic T-Cell-Depleted PBSC Transplantation (Summary Last Modified 06/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 to 45				NCI				FHCRC-696.2 NCI-H94-0411

Last Modified: 3/1/1999


10.		Phase I Study of Cellular Adoptive Immunotherapy with Epstein-Barr Virus (EBV)-Specific Cytotoxic T-Cells Following Chemotherapy for Refractory or Recurrent EBV-Expressing, HIV-Associated, Intermediate-or High-Grade B-Cell non-Hodgkin's Lymphoma (Summary Last Modified 03/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 to 45				NCI				DUMC-BB-IND-5464 NCI-V97-1123

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute